

Barbara Schroeder de Castro Lopes

lic. iur., LL.M. (Bruges), attorney at law

Judith Schallnau

LL.M. (Bruges), attorney at law

Life Sciences Law

Summary of contents

Preface	III
Foreword	VII
Summary of contents	IX
Table of contents	XI
List of abbreviations	XXI
Bibliography	XXXIII
Chapter 1: Introduction	1
§ 1 What is life sciences law?	1
§ 2 Structure of the book	1
§ 3 Key legal issues in life sciences at a glance	3
Chapter 2: Research and innovation	6
§ 4 Switzerland as a research location	6
§ 5 Discovery and prototypes	20
§ 6 Technology transfer	24
§ 7 Research with microorganisms	26
§ 8 Human research	33
Chapter 3: Market access	70
§ 9 Overview of the legislative framework	70
§ 10 Marketing authorisation for medicinal products	82
§ 11 Conformity assessment for medical devices	93
§ 12 Pricing and reimbursement	105
Chapter 4: Market-related activities	117
§ 13 Manufacturing	118
§ 14 Distribution	123
§ 15 Market surveillance and vigilance	135

Summary of contents

§ 16 International trade: import and export	141
§ 17 Product liability	153
Chapter 5: Cross-cutting issues in life sciences law	160
§ 18 Intellectual property	160
§ 19 Commercial contracts	216
§ 20 Dispute resolution	243
§ 21 Incorporation and fundraising	264
§ 22 Competition law	272
§ 23 Data protection and data transparency	284
Chapter 6: Selected legal issues in life sciences in the USA and China	298
§ 24 Protecting pharmaceuticals in the United States	298
§ 25 Regulatory framework of drug entry to China	304
Glossary	309

Table of contents

Preface	III
Foreword	VII
Summary of contents	IX
Table of contents	XI
List of abbreviations	XXI
Bibliography	XXXIII
Chapter 1: Introduction	1
§ 1 What is life sciences law?	1
§ 2 Structure of the book	1
§ 3 Key legal issues in life sciences at a glance	3
Chapter 2: Research and innovation	6
§ 4 Switzerland as a research location	6
1. Policy frame and stakeholders	6
2. Overview: the framework of Swiss research and technology legislation in life sciences	8
3. Research and innovation funding	13
a) Public funding	14
aa) National	14
bb) European Union	15
b) Private funding	19
§ 5 Discovery and prototypes	20
1. Pharma/biotech	20
2. Medical devices	22
§ 6 Technology transfer	24
1. Technology transfer offices	24
2. Main instruments of technology transfer	25
§ 7 Research with microorganisms	26
1. Biosafety in gene technology and diagnostic laboratories	26

Table of contents

a)	Biosafety legislation in Switzerland for activities in contained systems	26
b)	Risk determination and assessment according to the ContainO	27
2.	Biosecurity	29
3.	Biodiversity: access and benefit sharing	30
§ 8	Human research	33
1.	The Swiss legal framework	34
a)	The Human Research Act	34
b)	Other regulations relevant for human research	36
2.	Types of human research projects	37
a)	Clinical trials	37
aa)	What is a clinical trial?	38
bb)	Clinical trials in pharma/biotech and medtech: common framework and differences	38
cc)	Preclinical phase: <i>in vitro</i> and <i>in vivo</i> testing	39
dd)	Clinical trials with medicinal products	43
ee)	Clinical trials with medical devices	45
b)	Other (non-clinical) human research projects	47
3.	Key principles for all human research projects	47
a)	Scientific relevance	48
b)	Right to self-determination and informed consent of the research participant	49
c)	Subsidiarity and proportionality	50
d)	Additional requirements for studies involving vulnerable persons	51
e)	Prior independent assessment	51
4.	Who is involved in human research projects?	53
5.	Requesting approval for a human research project: practical guidance	54
a)	Clinical trial categories	54
aa)	Clinical trials with medicinal products	54
bb)	Clinical trials with medical devices	56
b)	Categories of other (non-clinical) human research projects	57
c)	How to submit an approval request to the Swiss authorities	57

6.	Conducting a human research project: ensuring safety of the research participants	58
a)	General notification and reporting requirements	59
b)	Adverse event documentation and notification	59
c)	Inspections carried out by Swissmedic	60
7.	Liability in case of damage suffered by research participants	60
8.	The new EU regulation on clinical trials with medicinal products	63
9.	The new EU regulations on clinical evidence for medical devices	65
a)	Clinical evaluation	65
b)	Clinical investigation	66
c)	Equivalence ("literature route")	67
d)	Performance evaluation and performance studies with IVDs	68
e)	Amendment of the Swiss HRA	68
Chapter 3:	Market access	70
§ 9	Overview of the legislative framework	70
1.	Therapeutic Product Act: concept, recently enacted and forthcoming amendments	70
2.	Other legislation of relevance for market access of therapeutic products	74
3.	Product classification and practical consequences	75
a)	Medicinal products vs medical devices	75
b)	Medicinal products/medical devices in relation to other product groups	79
c)	Excursus: mHealth – standalone software as medical device	80
§ 10	Marketing authorisation for medicinal products	82
1.	Marketing authorisation for medicinal products in Switzerland	82
a)	Criteria for marketing authorisation	82
b)	Marketing authorisation procedures	83
c)	Regulatory incentives	87
d)	Paediatric and orphan medicines	87

Table of contents

aa) Paediatric medicines	87
bb) Orphan drugs	88
2. Marketing authorisation for medicinal products in the EU	90
§ 11 Conformity assessment for medical devices	93
1. Basic rules and recent legislative changes	93
2. Common concepts for all medical devices	97
3. Specific provisions for active implantable and classical medical devices	99
4. Specific provisions for <i>in vitro</i> diagnostics	103
§ 12 Pricing and reimbursement	105
1. Policy considerations	105
2. Pricing and reimbursing medicinal products	107
a) Medicines eligible for reimbursement	107
b) Admission procedure and decision	109
c) Review of admission criteria	111
aa) Pre-market stage/non-listed medicines	112
bb) First admission, triennial reviews, new indication, new packaging	112
cc) After patent expiry	113
d) Foreign reimbursement systems and new approaches to pharma pricing	113
3. Pricing and reimbursing medical devices	114
Chapter 4: Market-related activities	117
§ 13 Manufacturing	118
1. Manufacturing medicinal products	118
a) Regulatory issues	118
aa) Manufacturing authorisation	118
bb) Good manufacturing practice	118
cc) Environmental issues	119
b) Commercial and technical aspects	120
2. Manufacturing medical devices	120
a) Regulatory issues	120
aa) No authorisation required	120
bb) Environmental issues	122
b) Commercial and technical aspects	122

§ 14	Distribution	123
1.	Distributing medicinal products	123
a)	Distribution channels	123
b)	Wholesale authorisation	123
c)	Good distribution practice	124
d)	Retail authorisation, dispensing doctors and online pharmacies	124
e)	Supply categories	125
f)	Advertising	127
g)	Integrity and transparency	128
h)	Organising distribution – commercial aspects	131
2.	Distributing medical devices	131
a)	Distribution channels	131
b)	No authorisation required	131
c)	Distance sales/e-commerce	132
d)	Regulatory responsibilities of economic operators in the supply chain and device traceability	133
e)	Advertising	134
f)	Integrity and transparency	134
g)	Organising distribution – commercial aspects	135
§ 15	Market surveillance and vigilance	135
1.	Market surveillance	135
2.	Market surveillance tools	136
3.	Pharmacovigilance and safety risk management	137
a)	Pharmacovigilance planning	138
b)	Periodic reporting and spontaneous notification requirements	138
4.	Materiovigilance and medical devices observation systems	140
§ 16	International trade: import and export	141
1.	The significance of the Switzerland-EU Mutual Recognition Agreement	142
a)	Significance for the pharmaceutical industry	142
b)	Significance for the medtech industry	144
c)	Market access for a non-European medical device manufacturer	147

Table of contents

d) What about the relationship between Switzerland and the EEA/EFTA countries?	147
2. Import and export authorisations for medicinal products – EU and non-EU	148
3. Exporting medical devices outside Europe	149
4. Parallel trade	150
5. Counterfeit and falsified medicines and medical devices	151
§ 17 Product liability	153
1. Doctor-patient relationship	153
2. Liability of the manufacturer towards the patient	154
a) Introduction	154
b) Particular issues and developments in relation to medicines	155
c) Particular issues and developments in relation to medical devices	157
Chapter 5: Cross-cutting issues in life sciences law	160
§ 18 Intellectual property	160
1. Introduction	160
2. Selected IP legislation and institutions	161
3. Patents	163
a) The legal framework	163
b) Definition, examples and scope of patent protection	164
c) Formal requirements – filing a patent application	165
aa) Where to file	165
bb) The patent application	167
cc) Priority	169
dd) Patent searches	169
ee) Application strategies and patent portfolio management	170
d) Substantive requirements – patentability criteria	172
aa) General conditions	172
bb) Exceptions to patentability	174
e) Effects of the patent	176
aa) General rule	176
bb) Exceptions	176
cc) Exhaustion and parallel imports	178

dd) Prior use	178
f) Extending patent term	179
aa) Supplementary Protection Certificate (SPC)	180
bb) Paediatric Extension	183
cc) Paediatric Certificate	185
g) Data exclusivity and market exclusivity	186
h) Integrated protection strategies	188
4. Trade marks	189
a) The legal framework	190
b) Definition, examples and scope of trade mark protection	190
c) Formal requirements – trade mark registration	192
d) Trade mark search and creation	193
aa) Overview	193
bb) Considerations for the trade mark selection process	193
cc) Trade mark portfolio management	194
e) Substantive requirements – absolute grounds to refuse trade mark registration	195
aa) Absolute grounds for refusal – overview	195
bb) International Non-proprietary Names (INNs) – signs that are in the public domain	196
f) Substantive requirements – relative grounds to refuse trade mark registration	198
g) Regulatory approval of medicinal product name	199
h) Trade mark term	200
i) Trade mark use	201
5. Design rights	201
a) The legal framework	201
b) Definition, scope and examples	201
c) Design registration	202
d) Duration of design protection	203
e) Designs and other IPR	203
6. Copyright	204
7. Database rights	205
8. Confidential trade secrets/know-how	205
9. Intellectual property enforcement	206

Table of contents

a) General overview – patents, trade marks, design, copyright enforcement	208
b) Patent litigation	214
c) Domain name cybersquatting	215
§ 19 Commercial contracts	216
1. Introduction	216
2. General considerations for negotiating and drafting contracts	217
a) Clarity	217
b) Transparency	218
c) Balanced relationship	218
d) Level of detail	218
3. Selected general contract terms	218
a) Parties, preamble, definitions	219
b) Term/termination	219
c) Confidentiality	219
d) Liability/indemnification	220
e) Representations and warranties	220
f) Intellectual property rights	220
g) Provisions on costs, budget, payment schedule, invoicing	221
h) Applicable law	221
i) Dispute resolution	221
4. Non-disclosure agreements	222
5. Material transfer agreements	222
6. Feasibility study agreements	223
7. Option agreements	224
8. Research and development agreements	225
a) Collaborative research	226
b) Contract research	229
c) Agreements related to clinical trials	229
aa) Clinical research organisation master services agreement	229
bb) Clinical trial agreement/contract for conducting clinical investigation in medical devices	231
9. Licence agreements	232
a) Legal framework	233

b)	Categories of licences	233
c)	Contract provisions	235
10.	Assignments	236
11.	Manufacturing agreements	237
12.	Distribution and supply agreements	239
§ 20	Dispute resolution	243
1.	Public law litigation	243
a)	Legal remedies against a decision issued by a cantonal authority	244
b)	Legal remedies against a decision issued by a federal authority	245
2.	Civil law and commercial litigation	246
3.	Patent litigation	249
4.	Mediation and arbitration	250
a)	Mediation	251
b)	Arbitration	253
c)	Benefits of mediation and arbitration	254
d)	How a mediation runs	259
e)	How an arbitration runs	260
f)	Dispute resolution clause example	262
§ 21	Incorporation and fundraising	264
1.	Preparatory stage	265
2.	Incorporation	266
3.	Fundraising and funding cycle	267
a)	Investor pitches and preparation for fundraising	267
b)	From “seed” funding to “exit”	268
§ 22	Competition law	272
1.	Overview	272
a)	Basic principles and enforcement authorities	272
b)	Particularities related to the pharmaceutical sector	276
2.	Selected issues and case examples	276
a)	Competition issues along the pharmaceutical value chain	276
b)	Scope of competition law	277
c)	Market definition	278
d)	Cartels	279

Table of contents

e)	Issues at the interface of IP, regulatory and competition law	279
aa)	Recent case law of European courts	280
bb)	Block Exemption Regulations (BERs)	282
cc)	Parallel imports	283
§ 23	Data protection and data transparency	284
1.	The legal framework in Switzerland	287
a)	Overview	287
b)	Biomedical research with biological material, genetic and non-genetic health-related data	288
2.	The new EU regulations	291
a)	Data protection: The General Data Protection Regulation and the Regulation on Clinical Trials	291
aa)	The EU-GDPR: General overview	291
bb)	Issues of particular relevance in life sciences	293
b)	Data transparency: The EU Regulation on Clinical Trials	296
Chapter 6:	Selected legal issues in life sciences in the USA and China	298
§ 24	Protecting pharmaceuticals in the United States	298
1.	Introduction	298
2.	Patents	298
a)	United States patent protection	298
b)	Enforcing patents	299
3.	FDA regulatory exclusivity	301
a)	Overview	301
b)	Small molecule drugs	301
c)	Biological products	303
§ 25	Regulatory framework of drug entry to China	304
1.	Introduction	304
a)	Key regulatory bodies	304
b)	Regulatory framework	305
2.	Clinical trials	305
3.	Manufacturing	306
4.	Drug importation	307
Glossary		309